| 영문 | hepatic portal system | 한글 | 간문맥계 |
|---|---|---|---|
| 설명 | 위, 작은창자이나 큰창자에서 영양분을 흡수하기 위한 모세혈관조직은 모두 간으로 연결된다. 즉 소화기에 흡수한 영양분이 가득한 피는 모두 간으로 연결되는데 이것을 문맥계라고 한다. |
||
| 영문 | system | 한글 | 계, 계통 |
|---|---|---|---|
| 설명 | 인체를 구성하는 계는 다음과 같이 구분된다. 1) 심장혈관계통(cardiovascular system) 2) 호흡기계(respiratory system) 3) 소화기계(digeshive system) 4) 비뇨기계(urinary system) 5) 생식기계(genital system) 6) 혈액계(hematologic system) 7) 내분비계(endocrine system) 8) 신경계(nervous system) 9) 골격계(skeletal system) 10) 근육계(muscular system) 11) 피부계(integumentary system). |
||
| 영문 | sympathetic nervous system | 한글 | 교감신경계 |
|---|---|---|---|
| 설명 | 자율신경계의 일종으로 내장기능을 주로 항진시켜 활동을 증가시키는 기능을 가진다. 자율신경계의 다른 계열인 부교감신경계는 반대로 내장기능을 억제시켜 에너지를 비축하는 기능을 가진다. 자율신경계의 해부학적 특성은 신경이 중추신경계에서 나와 목표장기에 도달하기 전에 한번의 시냅스(synapse)를 이룬다는 점이며, 따라서 자율신경계는 두 개의 신경(시냅스를 이루기 전의 절전신경과 이룬 후의 절후신경)으로 구성된다. 자율신경계중 교감신경계는 중추신경계 즉 척수 부근의 교감신경절(sympathetic ganglion)에서 시냅스가 일어나고, 부교감 신경계는 중추신경계에서 멀리 떨어진 목표 장기부근의 신경절(ganglion)에서 시냅스가 일어나는 점이 다르다. |
||
| 영문 | musculoskeletal System | 한글 | 근골격계 |
|---|---|---|---|
| 설명 | 근육과 이들 근육이 붙어서 같이 활동을 수행하는 골격(뼈를 통털어 말함)을 함께 부르는 말. 따라서 여기의 근육은 모두 가로무늬근에 속하며, 수의적으로 움직일 수 있다. |
||
| 영문 | muscular system | 한글 | 근육계통 |
|---|---|---|---|
| 설명 | 근육에 의해 이루어진 하나의 계통을 임의적으로 나누어 부른 말. |
||
| HCG, hCG | Human Chorionic Gonadotropin; 사람융모성성선자극호르몬 1. Placental Glycoprotein Hormone &nbs... |
|---|---|
| ICU | infant care unit; immunologic contact urticaria; intensive care unit; intermediate care unit |
| OILD | occupational immunologic lung disease |
| ISIS | image selected in vivo spectroscopy; imaging science and information system; information system-imag... |
| MDS | Master of Dental Surgery; maternal deprivation syndrome; medical data screening; medical data system... |
| T system | tubular system |
|---|---|
| AMS | AUTO-MICROBIC-SYSTEM |
| ARMS | Amplification Refractory Mutation System |
| AIMS | Anaesthesia Information Management System |
| ARIS | Apoenzyme Reactivation Immunoassay System |
| adjuvants, immunologic | Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (freund's adjuvant, bcg, corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (12 Dec 1998) |
|---|---|
| receptors, immunologic | Cell surface molecules on cells of the immune system that specifically bind surface molecules or messenger molecules and trigger changes in the behaviour of cells. Although these receptors were first identified in the immune system, many have important functions elsewhere. (12 Dec 1998) |
| graft enhancement, immunologic | The induction of prolonged survival and growth of allografts of either tumours or normal tissues which would ordinarily be rejected. It may be induced passively by introducing graft-specific antibodies from previously immunised donors, which bind to the graft's surface antigens, masking them from recognition by T-cells; or actively by prior immunization of the recipient with graft antigens which evoke specific antibodies and form antigen-antibody complexes which bind to the antigen receptor sites of the T-cells and block their cytotoxic activity. (12 Dec 1998) |
| monitoring, immunologic | Testing of immune status in the diagnosis and therapy of cancer, immunoproliferative and immunodeficiency disorders, and autoimmune abnormalities. Changes in immune parameters are of special significance before, during and following organ transplantation. Strategies include measurement of tumour antigen and other markers (often by radioimmunoassay), studies of cellular or humoral immunity in cancer aetiology, immunotherapy trials, etc. (12 Dec 1998) |
| contraception, immunologic | Contraceptive methods utilizing immunologic processes. (12 Dec 1998) |
| cytotoxicity, immunologic | The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitised T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. (12 Dec 1998) |
| cytotoxicity tests, immunologic | The demonstration of the cytotoxic effect on a target cell of a lymphocyte, a mediator released by a sensitised lymphocyte, an antibody, or complement. (12 Dec 1998) |
| suppressor factors, immunologic | Proteins, protein complexes, or glycoproteins secreted by suppressor T-cells that inhibit either subsequent T-cells, B-cells, or other immunologic phenomena. Some of these factors have both histocompatibility (I-j) and antigen-specific domains which may be linked by disulfide bridges. They can be elicited by haptens or other antigens and may be mass-produced by hybridomas or monoclones in the laboratory. (12 Dec 1998) |
| desensitization, immunologic | Immunosuppression by the administration of increasing doses of antigen. Though the exact mechanism is not clear, the therapy results in an increase in serum levels of allergen-specific IgG, suppression of specific IgE, and an increase in suppressor T-cell activity. (12 Dec 1998) |
| dose-response relationship, immunologic | A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell. (12 Dec 1998) |
| immunologic | <immunology> Pertaining to immunology. (18 Nov 1997) |
| immunologic and biological factors | A collective grouping for biologically active substances that play a role in the functioning of the immune system and those that show biological or physiological activity. (12 Dec 1998) |
| immunologic capping | The process by which lymphoid cell surface immunoglobulin receptors, when exposed to bivalent anti-ig antibodies, collect in patches and form a cap at one pole of the cell. The caps may then be endocytosed or shed into the environment in the form of antigen-antibody complexes. Capping has also been induced by lectins and antigens. (12 Dec 1998) |
| immunologic deficiency syndromes | Syndromes in which there is a deficiency or defect in the mechanisms of immunity, either cellular or humoral. (12 Dec 1998) |
| immunologic diseases | Disorders caused by abnormal or absent immunologic mechanisms, whether humoral, cell-mediated or both. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|